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Abstract The biologics used in transplantation clinical prac-
tice include several monoclonal and polyclonal antibodies
aimed at specific cellular receptors. The effect of their mech-
anisms of action includes depleting or blocking specific cell
subpopulations, complement system, or removing circulating
preformed antibodies and blocking their production. They are
used in induction, desensitization ABO-incompatible renal
transplantation, rescue therapy of steroid-resistant acute rejec-
tion, treatment of posttransplant recurrence of primary disease
such as nephrotic syndrome or atypical hemolytic–uremic
syndrome, and in late humoral rejection. There are various
indications for the use of biologic agents before and early or
late after renal transplantation in both high- and low-risk
recipients. In the latter situation, the biologics-based induction
is used to further minimize immunosuppression maintenance.
The targets of several biologic agents are present across a
variety of cells, and manipulation of the immune system with
biologics may be associated with significant risk of acute and
late-onset adverse events; therefore, clinical risk-versus-
benefit ratio must be carefully balanced in every case.
Several trials on novel biologics are reported in adults but
not in the pediatric population.
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Introduction
Biologic agents used in renal transplantation include several
drugs of different mechanisms of action, given intravenously,
aimed at blocking or depleting specific cell subpopulations or
blocking circulating alloantibody responses or the complement
system. From a clinical standpoint, they are used in induction,
desensitization procedures in hyperimmunized patients, ABO-
incompatible renal transplantation, treatment of steroid-resistant
and/or humoral rejection, and therapy for recurrence of specific
primary renal disease, such as nephrotic syndrome (NS) or
atypical hemolytic uremic syndrome (aHUS) (Fig. 1). They
are used before and early or late after renal transplantation in
both high- and low-risk recipients (Fig. 2). Several biologic
agents are used in clinical practice in pediatric renal transplan-
tation; however, the majority is used off-label, and their dose
range and optimal number of doses are not clearly defined. This
review summarizes data on experience, efficacy, and safety of
biologics used in renal transplantation in children and on emerg-
ing new agents, used only in adult practice or clinical trials, that
have not yet been verified in the pediatric setting. Drugs used in
children include monoclonal antibodies (MAb) daclizumab,
basiliximab, and alemtuzumab; polyclonal antibodies
thymoglobulin or ATGAM [lymphocyte immune globulin,
antithymocyte globulin (equine) sterile solution], specific
MAb such as rituximab and eculizumab; and human immuno-
globulin preparations [intravenous immunoglobulins (IVIG)].
Targets for and mechanisms of action of these agents are
presented in Table 1. Indications, duration of action, and
specific monitoring are presented in Table 2 [1–3, 11–19,
21–23, 25–28, 39, 42–47, 49, 53, 56, 57, 62–64]. A variety of
new drugs were investigated in several clinical trials that recruit-
ed adult renal graft recipients [3, 4]. These new molecules were
used to desensitize high-risk patients, in induction protocols, and
to treat humoral rejection. Emerging new drugs and their spe-
cific targets in the immune system are listed in Table 3 [4];
clinical experience from clinical trials in adult patients is sum-
marized in Table 4 [4–10], and evidence-based (EB) clinical
experience in the pediatric population is presented in Table 5
[11–19, 21–23, 25–28, 33, 39, 42–47, 49, 53, 56, 57, 62–64].
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Biologics in induction
Induction is the most common indication to use biologic
agents in pediatric renal graft recipients. It is used for two
reasons: (1) to enhance the strength of initial triple immu-
nosuppression in patients with high immunological risk
[sensitized, retransplanted, poor human leukocyte antigen
(HLA) matching or marginal donor transplant] or (2) to
introduce minimization protocol aimed at reducing expo-
sure to steroids or calcineurin inhibitors (CNI), or both. In
the second indication, MAbs were used in patients with
low immunological risk and polyclonal Ab in patients
with low and high immunological risk.
MAb used in pediatric transplantation include anti-CD25
(IL-2Rα) inhibitors daclizumab and basiliximab and anti-
CD52-depleting Ab alemtuzumab used off label. The duration
of effect (for two doses of basiliximab) expressed as receptor
saturation was present at about 5 weeks with no mycopheno-
late mofetil (MMF) and about 10 weeks with concomitant
MMF therapy [11]. In the Stanford steroid avoidance trial, the
trough concentration of daclizumab was monitored by se-
quential sandwich enzyme-linked immunosorbent assay
(ELISA); however, routinely, no specific monitoring is used
in practice [12]. Comprehensive information on efficacy and
safety of anti-CD25 inhibitors basiliximab and daclizumab,

















Fig. 1 Indications to use



























*off-label or under investigation
Fig. 2 Timing biologic use in renal transplantation
1088 Pediatr Nephrol (2015) 30:1087–1098
from a Cochrane database large systematic review involving
71 adult and pediatric trials and 10,520 participants. Use of
both daclizumab and basiliximab given in induction decreased
the risk of acute rejection in the first year after transplantation
by 25 % [relative risk (RR) 0.75], as well as incidence of 1-
year graft loss by 25 % [13]. Two pediatric randomized
controlled trials (RCTs) proved that adding anti-CD25 Ab
basiliximab to triple-maintenance protocol tacrolimus/
azathioprine/prednisolone (TAC/AZA/Pred) or cyclosporin
A/MMF/Pred (CsA/MMF/Pred) in patients of low to moder-
ate immunological risk is not justified, as the incidence of
rejection and patient and graft survival was no different in
children with or without induction [14, 15]. Monoclonal in-
duction was also used in a majority of pediatric clinical trials
on steroid minimization. The Stanford complete steroid avoid-
ance study was based on an extended daclizumab induction
(overall nine doses) [12]. Only two daclizumab doses of
1 mg/kg were used in the TWIST trial, and steroids were
stopped at day 5 after surgery [16]. It should be noted that
daclizumab is no longer manufactured, and two doses of
basiliximab were used in further pediatric trials on steroid
withdrawal [17–19]. Early and long-term results of all these
and other trials have shown that in pediatric patients with low
to moderate immunological risk, monoclonal induction with
anti-CD25 Ab with combination TAC/MMF therapy was
sufficient to allow early steroid withdrawal, resulting in all
expected clinical benefits, including better growth, with no
detrimental effect on long-term patient/graft survival and renal
function [20]. Basiliximab was also used in the innovative
protocol, which aimed to double the minimization of immu-
nosuppression (CNI plus steroids). With monoclonal induc-
tion and use of everolimus, reduced exposure to cyclosporine
was possible; in further follow-up, with a normal renal biopsy,
the late (> 6 months after transplantation) steroid withdrawal
was also possible. This protocol was very effective in patients
at low immunological risk, with no rejection within 1 year and
with 100 % patient and graft survival in the 3-year follow-up
[21]. The ongoing multicenter CRADLE RCT aims at verify-
ing the efficacy and safety of a similar protocol but with Csa
replaced by TAC, especially in the subgroup of patients given
basiliximab, as monoclonal induction with basiliximab is not
mandatory in this trial and depends on the individual decisions
of each center (www.clinicaltr ials.gov/ct2/show/
NCT01544491).
Induction with basiliximab and the then new drug
belatacept, administered IV every 2 weeks then repeated
Table 1 Biologic agents used in
pediatric renal transplantation in
clinical practice: targets in the
immune system and mechanisms




(equine) sterile solution, IVIG in-
travenous immunoglobulins, IgG
immunoglobulin G, IL-2 inter-
leukin-2,APC antigen-presenting
cells, HLA human leukocyte anti-
gen, NK natural killer





(IL-2 receptor α chain)
Binds to and blocks IL-2 receptor on T cells,
inhibiting IL-2-induced T-cell activation
Alemtuzumab
(humanized MAb)
CD52 Binds to CD52 receptor on T and B cells,
monocytes, macrophages, and NK cells,
resulting cell lysis and long-lasting depletion




Complement protein C5 Binds to complement protein C5, inhibiting
its cleavage to C5a and C5b and




T cells: CD3, CD4, CD8,
CD58, CD28 and others









Blocks several T- and B-cell receptors,






Related to antibody and B cells
(selected mechanisms):
Anti-idiotypic blockade of alloantibodies
Downregulation of Ab production
Increased catabolism of IgG caspase and
mitochondrial-induced apoptosis of B cells
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infusions every 4 weeks, was used for prophylaxis of
acute rejection in adult patients after renal transplantation,
randomized to three arms, including two with different
dosages of belatacept and one with CsA, all combined
with MMF and steroids. At 1 year, both belatacept arms
showed no inferiority to the CsA arm in terms of graft and
patient survival, with better renal function in belatacept
arms. An important clinical benefit was better metabolic
profile in belatacept-treated patients; however, there was a
safety concern related to high posttransplant lymphopro-
liferative disease (PTLD) rate in Epstein-Barr virus
(EBV)-seronegative patients [5]. Another option of mono-
clonal antibody induction was the use of alemtuzumab,
primarily in children, by Pittsburgh group, who used the
single dose of 0.4–0.5 mg/kg, followed by TAC mono-
therapy and early steroid withdrawal (at 1–5 days after
transplantation). Using this approach and long-lasting de-
pletion of target cells, maintenance immunosuppression
was limited to TAC monotherapy [22, 23].
An innovative protocol of alemtuzumab induction (30 mg/
dose) with monthly belatacept IV (10 mg/kg/dose) and daily
sirolimus given after renal transplantation to avoid calcineurin
and steroid exposure in 20 adult renal transplant recipients
was recently reported. There was no acute rejection or de novo
donor-specific antibody (DSA) production within the first
year. Ten patients remained on belatacept as the single immu-
nosuppressive drug [24].
Polyclonal induction
In a retrospective single-center study, 198 children and
adolescents were given polyclonal combined with triple-
maintenance regimen. Significantly fewer episodes of
acute rejection were seen in patients treated with
thymoglobulin (33 % vs 50 %, p=0.02) [25]. Overall,
37 adolescents (mean age 15.2±2.8 years) were treated
with the induction protocol, including five to seven fixed
doses of 1.5 mg/kg thymoglobulin combined with TAC/
MMF/Pred; there was an 8.1 % incidence of acute rejec-
tion within 1 year and 91.9 % graft and 100 % patient
survival [26]. Six fixed doses of 1.5 mg/kg thymoglobulin
induction were used by the Stanford group in an early
steroid withdrawal protocol in 13 children with high im-
munological risk, with no further rejection episode within
Table 2 Biologic agents used in pediatric renal transplantation in clinical practice: indications, duration of effect, and monitoring




Basiliximab MAb induction up to 56 days
(with 2 doses)
Receptor CD20 saturation




Daclizumab* MAb induction number of doses,
dependent effect
receptor CD20 saturation
or drug concentration in
serum (not routinely used)
2-6
Alemtuzumab*** MAb Induction; treatment
of rejection
(not routine)






















polyclonal ab induction; steroid-resistant
rejection






IVIG Immunoglobulin Desensitization **** no 2-6
ATG antithymocyte globulin, Ab antibodies, MAb monoclonal antibodies, aHUS atypical hemolytic uremic syndrome, IVIG intravenous immuno-
globulin G, TTC terminal complement complex, CH50 50 % hemolytic complement activity, WBC white blood cell
*not available since 2009
**undefined number of doses in prophylaxis of genetic HUS recurrence after renal transplantation
*** off-label in transplantation
**** duration of IVIG effect on circulating Ab is difficult to evaluate, as their further production is blocked by rituximab given simultaneously (in
nonplasmapheresis protocols); significant decrease in anti-HLA Ab class II titer as early as from days 10–20 after first dose of IVIG was reported [35]
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1-year follow-up, normal picture biopsies performed ev-
ery 3 months up to 1 year after transplantation, and no de
novo DSA [27]. Overall, five to seven doses of 1.5 mg/kg
thymoglobulin were given to 21 pediatric patients under-
going an early steroid minimization protocol compared
with six to 15 doses given as steroid maintenance (retro-
spective control group). With steroid withdrawal on day 6,
the incidence of acute rejection was 23 % and graft
survival 90 % at 1 year, which was no different than in
controls [28].
The optimal number of thymoglobulin doses (days of
treatment) in induction protocols is not defined. The attempt
to keep optimal balance between efficacy and safety is the
basis of using short (<3 doses) or longer (up to 10 doses)
induction and adjusting the dose to trough CD3 (target 50–
100/mm3) or WBC count (target>3000/mm3) versus a fixed
dose of 1.5 mg/kg [29, 30]. The median cumulative dose in
adult renal graft recipients in TAILOR registry data was
5 mg/kg per treatment (1.56-15.00); 46.6 % of patients (over-
all n=2,322) received between 1.5 and 5 mg/kg, 35.4 % from
5 to 7 mg/kg, and 18 % from 7 to 15 mg/kg per treatment. Up
to 64.6 % of patients tolerated the full intended induction dose
[31]. The US Organ Procurement and Transplantation
Network (OPTN) database stratified the incidence of based
Table 3 New investigational agents (not used in pediatric clinical practice or evaluated in pediatric clinical trials)
Agent Target Suggested mechanism of action
Belatacept CD80 (B7-1), CD86 (B7-2) on APCs Blockade of pathway preventing production of IL-2 and conversion
of naïve T cells into effector T cells
Alefacept* CD2 on T cells Co-stimulation inhibitor. Preferential depletion of effector T cells
Natalizumab VLA-4 on lymphocytes Blockade of interaction between VLA-4 and VCAM-1 and impairment
of lymphocyte trafficking into tissues
Efalizumab* LFA-1 (CD11a) on leukocytes Competitive inhibition with ICAM-1 located on APCs and impairment
of lymphocyte adhesion and activation
Tasocitinib (tofacitinib) JAK3 (JANUS tyrosine kinase) Inhibiting signaling cascade by blocking transcriptive factors Stat 5a i Stat 5b
Bortezomib Proteasome Inhibiting degradation of cell-cycle regulatory proteins resulting in cell-cycle
arrest and apoptosis; inhibiting degradation of inhibitor κB, therefore
preventing NFκB-mediated cell activation
ASKP1240 CD40 Blockade of CD40-positive cells





VLA-4 very late antigen-4, NFκB nuclear factor kappa B
*No further investigation in transplantation
Table 4 Clinical experience with novel drugs (still being investigated) in adult transplant populations
Agent Major reports Clinical indication;
treated populations

















RCT Induction: adults (n=40,
in two treatment arms)
Not inferior to CNI-based
triple regimen
High rate of viral infection
Dyslipidemia
ASKP1240 RCT Induction: overall 38
(3 treatment arms)
Not inferior to CNI-based
triple regimen
Significant rate of infections




Promising Anemia; peripheral neuropathy
RCT randomized controlled trial CNS central nervous system, CNI calcineurine inhibitor, PTLD posttransplant lymphoproliferative disease, EBV
Epstein–Barr virus
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on depleting and nondepleting agents: lymphocyte-depleting
Ab were used in 47.5 % and IL-2R antibodies in 43 % of
1,276 children treated with steroid minimization protocols and
induction between 2002 and 2009 [32].
Summarizing: induction with biologic agents, such as anti-
IL2 Ab (basiliximab) or polyclonal Ab, after verification in
clinical trials and reports, has entered routine practice in
selected patients with clear clinical indications.
Biologics in desensitization of HLA-incompatible
renal-graft recipients
In patients awaiting renal transplantation, reducing the titer
of pre-formed anti-HLA antibodies by using plasmaphere-
sis (PF), IVIG administration alone, combined with PF, or
rituximab was reported in several adult studies and a few
pediatric case reports [33–35]. The most common protocol
used in adult patients in the USA was based on a combi-
nation of IVIG and PF (82 %), and preoperative rituximab
was used in more than half of reporting centers [36]. The
combination of IVIG and rituximab was used by Jordan’s
group to reduce the titer of pre-formed anti-HLA antibod-
ies in highly sensitized patients awaiting renal transplanta-
tion [37]. The authors described the protocol based on
administration of 2 g/kg IVIG on the days 0 and 30,
combined with rituximab (375 mg/m2) given on days 7
and 22 (after first dose if IVIG). This protocol caused
significant reduction of mean panel-reactive antibody
(PRA) level from 77±19 % to 44±30 % (p<0.0001) after
second infusion of IVIG and shortened the waiting time to
successful transplantation from 144±89 months to 5±
6 months. Regardless of the encouraging short-term re-
sults, the long–term efficacy of the desensitization protocol
was questioned in adult patients in a retrospective compar-
ative cohort study. The 1- and 5-year graft survival rate was
significantly inferior in patients who underwent the desen-
sitization protocol based on a course of PF combined with
IVIG and then depletional induction (89.9 vs 97.6 % and
69.4 vs 80.6 %, respectively). The overall risk of graft loss
was significantly higher in desensitized patients [hazard
ratio (HR) 2.6; p=0.04)] but with no detrimental effect
on patient survival [38].
Biologics in ABO-incompatible renal transplantation
Other specific desensitization protocol was used by Tyden
et al. in living- donor ABO-incompatible pediatric transplan-
tation. The pretransplant protocol included a single dose of
375 mg/m2 rituximab given 4 weeks before scheduled
immunoadsorption, triple immunosuppression, four sessions
of antigen-specific immunoadsorption, followed by 0.5 g/kg
IVIG preoperatively and continuation of immunoadsorption
after surgery. Five-year patients survival rate was 98 % and
graft survival rate 97 % [39], which are obviously not inferior
to outcomes in ABO-compatible transplantation. Eculizumab
was used to enhance the desensitization protocol (PF followed
by polyclonal induction) in adult patients undergoing living-
Table 5 Evidence-based medicine level of clinical experience with biologics in pediatric renal transplantation











1,503 Favorable graft and patient survival; clinical
benefit from steroid or/and CNI minimization




IVIG, rituximab Case series and case reports 65 Transplantation possible; shorter waiting time;
no proven long-term efficacy. Transplantation






Case series and case reports 38 Variable efficacy in NS. Effective prophylaxis in








case series and case reports
27 Variable efficacy in acute rejection
Treatment of chronic
humoral rejection
IVIG, rituximab Single-center prospective trials;
case series and case reports
26 Effective in majority (70 %) of reported patients
HLA human leukocyte antigen, AB antibodies, IVIG intravenous immunoglobulin, RCT randomized controlled trials, CNI calcinurine inhibitors, NS
nephrotic syndrome, aHUS atypical hemolytic uremic syndrome
*Overall number of patients means the sum of cases presented in quoted publications listed in the text, not the overall number of patients ever treated with
a particular drug
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donor renal transplantation against positive cross match in
terms of preventing antibody-mediated rejection (AMR).
Overall, 26 patients received preemptively 1,200 mg of
eculizumab immediately before transplantation, then 600 mg
on day 1, then four times weekly. Further dosing was adjusted
to the presence of DSA. The incidence of antibody-mediated
rejection (AMR) was 7.7 % vs 41.2 % in the control group
(p=0.0031) [40]. Bortezomib (4 x 1.3 g/m2) was given pre-
emptively (early posttransplant) to remove de novo DSA
(before expected further humoral rejection occurs). In a series
of 26 patients, bortezomib combined with steroids was given
within a mean of 30 days after DSA appearance (n=26), with
PF and rituximab (n=9), with PF only (n=5), or with IVIG
(n=1). There was significant reduction in DSA level at 1 year
(p=0.002), correlated with better allograft function at a mean
of 25.8 months of follow-up [41].
Summarizing: Desensitization of HLA-incompatible pa-
tients with biologic agents (or combination of biologics
with plasma exchange) allows further renal transplantation
and may shorten the waiting time for transplant. However,
these patients still present a high risk of rejection and
inferior long-term graft survival. This will be very impor-
tant in pediatric renal-graft recipients, who have a long life
expectancy on renal replacement therapy. A specific de-
sensitization protocol, as described by Tyden et al., allows
successful ABO-incompatible renal transplantation with
excellent long-term outcome.
Biologics in recurrence of primary disease after renal
transplantation
Eculizumab has been used in prophylaxis and treatment of
posttransplant recurrence of aHUS. The report by the
French Group for Atypical HUS assessed 22 pediatric
cases in their retrospective multicenter study. Thirteen
patients were treated due to recurrence, and nine received
pre-emptive eculizumab as prophylaxis. Single and mul-
tiple doses were given is cases presenting several CFH,
CFI, and C3 gene mutations. Some patients were resistant
to PF (n=10), and some were PF dependent (n=2). In
some cases, the picture of renal biopsy included signs of
acute rejection. All but one patient from the prophylaxis
group remained recurrence free at a mean 14.5-month
follow-up. In all 13 patients with recurrence, the hemato-
logical features of aHUS rapidly returned to normal fol-
lowing eculizumab administration, whereas mean creati-
nine concentration dropped from a mean of 295±171 to
135±69 μmol/L (p=0.002) within 3 subsequent months.
Patients with delayed introduction of eculizumab treat-
ment (>28 days after diagnosis) had lower functional
benefit than patients treated earlier after aHUS onset
[42]. Rituximab was used to treat recurrence of severe
NS in a series of children after renal transplantation. One
to four doses (of 375 mg/m2) were given, and complete or
partial response was observed in six of seven patients
[43]. Variable response to one to four doses of rituximab
was reported in series of eight patients; complete response
was seen in two and partial in four. In some cases, there
was a correlation between CD19 depletion and clinical
response and between CD19 recovery and relapses; in
others, there was no association between CD19 count
and clinical course of NS [44]. The efficacy of rituximab
(four doses) in a girl with Finnish-type congenital NS and
clinical “recurrence” due to anti-nephrin Ab production
was reported. Remission was sustained during the 5-year
follow-up [45].
Summarizing: recurrence of severe primary renal dis-
eases has become potentially treatable with currently avail-
able biologic agents (rituximab and eculizumab); however,
important limitations remain, including overall efficacy
and safety for rituximab and enormous financial cost for
eculizumab in prolonged prophylaxis.
Biologics in rejection therapy
Acute rejection
Acute rejection is associated with allograft infiltration by
several cell types, including T and B cells, macrophages,
and NK cells. Polyclonal Ab therapy is commonly used in
steroid-resistant cases. The significant presence of B cells
in biopsy-proven infiltrate may suggest that rituximab
might be useful. The Stanford group conducted a random-
ized trial comparing 4 weekly doses of rituximab
(375 mg/m2) versus thymoglobulin (6 x 1.5 mg/kg) in
20 pediatric renal recipients with late acute rejection
(mean time from transplantation to rejection 34 and
21.36 months) in two arms of ten patients each. All
patients were pretreated with methylprednisolone (MP). .
In six patients in the rituximab group and two from the
control group, humoral component of rejection was con-
firmed by CD4 presence. The presence of CD20 cells in
graft infiltrates was confirmed in all patients. Results
confirmed the efficacy of rituximab therapy in CD20-
positive acute rejection [46]. Limited efficacy of single-
dose (0.3 mg/kg) alemtuzumab in rescue treatment of late
acute cellular rejection was reported in three children at
high immunological risk, with recurrent episodes of rejec-
tion and poor previous response to other therapies (in-
cluding steroids and polyclonal Ab) [47]. More successful
treatment was described in 15 adult patients. The use of
multiple doses (4–10 days, dose 6–10 mg/kg) showed no
increase in malignancy or cytomegalovirus (CMV) infec-
tion over 10 years of follow-up despite, high doses used
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in this study [48]. Whether or not this difference in
efficacy was related to the use of single versus multiple
doses, rejection type, or patient specificity is not clear.
Three successful pediatric cases of ABR were reported
with the use of MP, 2 g/kg IVIG, a single dose of ritux-
imab (375 mg/m2), and course of plasma exchange (up to
ten procedures) [49]. The protocol proposed by Jordan
et al., based on clinical experience, distinguished patients
with less and more pronounced pathologic features of
ABR. Those with a milder clinical picture received a
combination of three MP pulses, initial dose of 2 g/kg
IVIG given between first and second pulses, and a single
dose of rituximab (375 mg/m2) on day 2, followed by two
consecutive MP pulses. The second (and last) dose of
2 g/kg IVIG was given between 30 and 60 days of
treatment. More severe cases, with signs of thrombotic
microangiopathy in biopsy, were treated with a series of
PF, followed by single doses of IVIG (2 g/kg) and a
single dose of rituximab (375 mg/m2) [50]. Bortezomib,
in a retrospective comparison with rituximab, was report-
ed in ten adult patients treated also with MP, PF (six
sessions), and IVIG (30 g/treatment) [51]. The efficacy
of bortezomib was lower in cases of late AMR, i.e.,
occurring>6 months after transplantation. Delay in diag-
nosis and difference in characteristics of cells producing
DSA in late-onset AMR (long-lived plasma-cell popula-
tion) is proposed as an explanation of a worse response
[52] . Ecu l i zumab was success fu l ly used in a
hyperimmunized 17-year-old patient with PF resistant of
acute humoral rejection, developing in the second graft,
after a desensitization protocol based on combined PF,
IVIG, and rituximab. The patient was treated with MP,
repeated PF, and IVIG; however, DSA and ongoing rejec-
tion persisted, proven in repeated biopsy, despite 45 ses-
sions of PF and absence of CD19 cells. Four doses of
eculizumab (600 mg) were given, and remission was pres-
ent at the third biopsy. Eculizumab was then continued on a
monthly basis (eight doses) due to increasing DSA titer,
which appeared after PF was stopped. Two years after
therapy, the patient was stable, with creatinine concentra-
tion of 1.2 mg/dl and DQ DSA of mean fluorescent inten-
sity (MFI) 5,000 [53]. Similar reports were published re-
garding eculizumab efficacy in highly sensitized adults
patients developing acute humoral rejection despite
pretransplant (PF/IVIG/rituximab) desensitization and use
of polyclonal induction; one to five doses of eculizumab
were used in rescue therapy [54, 55].
Chronic humoral rejection
The protocol described by Jordan et al. in patients with
chronic antibody-mediated rejection as a result of the
presence of de novo DSA had three options: IVIG alone,
IVIG plus rituximab, and combination of plasmapheresis
with lower dose of IVIG (1 g/kg) with or without ritux-
imab [50]. The combination of IVIG (4 × 1 g/kg) and a
single dose of rituximab (375 mg/m2) given 1 week after
last IVIG dose was reported as a therapeutic tool for
chronic humoral rejection in six children: four responded
to antirejection therapy and showed increased glomeru-
lar filtration rate (GFR) within 12 months: significantly
at 6 months by 21 ml/min/1.73 m2 (p<0.05) and then not
significantly at 12 months by 19 ml/min/1.73 m2 (p=
0.063) [56]. The same protocol (four doses of IVIG
1 g/kg plus a single dose of 375 mg/m2 rituximab) was
used in a prospective study recruiting 20 children with
Banff diagnostic criteria of Ab-mediated rejection togeth-
er with CD20-positive infiltrates (12 (60 %) patients).
The response rate was 70 % (14 patients) [57].
Bortezomib (4 × 1.3 g/m2) was used in adult patients
with humoral rejection as a single rescue agent or in
combination with IVIG or PF [58].
Summarizing: Availability of biologic agents increases
the range of therapeutic tools in resistant, acute, and hu-
moral chronic allograft rejection. However, selecting the
potentially most effective treatment protocol requires very
detailed diagnosis based on close DSA monitoring and
interpretation of results and relevant pathomorphologic
evaluation, including the phenotype of infiltrating cells (T
or B). There remains a need for further clinical investiga-
tion in this area.
Safety concerns with biologic agents in clinical practice
Biologic agents used in renal transplantation are highly
potent immunosuppressants, interfering with normal im-
mune response and therefore increasing the risk of spe-
cific complications. Their safety profile is variable and
might be dose dependent and related to cumulative side
effects of certain drugs combinations. The safety profile
of commonly used biologics is summarized in Table 6
[59–66].
Posttransplant lymphoproliferative disease
The risk of posttransplant lymphoproliferative disease
(PTLD) in pediatric renal graft recipients is higher than
in adults mainly due to higher incidence of EBV sero-
negativity in the first decade of life, and depletional
induction is regarded as an additional risk factor. The
incidence of PTLD was significantly higher in children<
10 years of age treated with polyclonal Ab [59, 60].
Analysis of PTLD risk relation used various antibodies
in 59,560 kidney recipients [data from the Organ
Procurement and Transplantation Network/United
Network for Organ Sharing (OPTN/UNOS)], including
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3,105 children, showed that only polyclonal induction
was associated with significant risk (RR 1.63, p=0.0025
vs no induction). Additional factors included age <18 years
(RR 3.67; p<0.0001), seronegative EBV (RR 5.225;
p<0.0001), CMV (RR 2.036; p<0.0001) status, and—inter-
estingly— the use of sirolimus in maintenance immunosup-
pression (RR 2.047; p<0.0001) [61]. A more recent report
provides data on a higher risk of PTLD in patients receiving
alemtuzumab for induction [62]. Pretransplant EBV seroneg-
ative status was also a risk factor of PTLD in children given
nondepletional induction with basiliximab combined with
sirolimus, tacrolimus, or cyclosporine, and steroids. Up to
6.9 % of patients developed PTLD. This was mainly seen in
young EBV-naïve children receiving an EBV-seropositive
renal allograft [18]. Of note is the specific relation of the
new drug belatacept to PTLD (in adult patients): in EBV-
seronegative cases, treatment was associated with a high
incidence of PTLD, affecting in particular the central nervous
system [5]. As the incidence of EBV-seronegative status is
much higher in the first decade of life [59], the safety of further
use of belatacept in pediatric patients is questionable.
Infections
As reported by North American Pediatric Renal Trials and
Collaborative Studies (NAPRTCS), induction is associated
with significant higher risk of infection [odds ratio (OR)
1.45; p<0.001), especially in terms of viral etiology (OR
1.47; p=0.003) and in young children<2 years of age, includ-
ing the risk of BK–JC polyoma-virus (JVC)-related nephritis.
The incidence of hospitalization within 2 years of follow-up
(after induction) due to viral infections was about 30 % and
bacterial infections about 28.4 % [63, 64]. Specific vaccination
is mandatory with the use of eculizumab to prevent meningitis
[42]. The association between treatment with rituximab JVC
and, in consequence, development of progressive multifocal
leukoencephalopathy (PML) was reported mainly in bone
marrow transplant patients. The relevant report described
5.5 % incidence of JVC replication in adult solid-organ recip-
ients (in the majority renal transplant patients) treated with
rituximab, suggesting the need for close monitoring [65].
Rituximab-specific serious adverse event:
rituximab-associated lung injury
Rituximab-associated lung injury was reported in patients
treated with anti-CD20 Ab. This life-threatening syndrome
may include interstitial pneumonitis, alveolar–interstitial
pneumonia, and rapidly progressing pulmonary fibrosis. The
need for mechanical ventilation is a predictor of poor progno-
sis [66].
Summarizing: Use of biologic agents is associated with
risk of several general or drug-specific adverse events; there-
fore, the risk/potential clinical benefit ratio must be carefully
balanced. EBV-seronegative status, the most common in chil-
dren < 10 years of age, is a specific problem in the pediatric
population and may limit or increase the risk of biologic agent
use.
Key points regarding the use of biologics in rejection
therapy are:
– Biologics are used in transplantation to remove circulat-
ing antibodies and block their production, to reduce fur-
ther exposure to toxic maintenance immunosuppressives,
to treat recurrence of specific primary disease, and to treat
severe rejection.






Alemtuzumab Rituximab Eculizumab IVIG
Cytokine release syndrome
(fever, chills, hypotension)
0/+ +++ + 0/+ 0 0
Hypersensitivity reactions ++ +++ + + + +
Bone marrow complications + +++ + + + 0
Lymphopenia + +++ +++ +++ 0 0
Malignances 0 ++ + 0 0 0
Viral infections (CMV, EBV, BKV, other) + +++ ++ + ++ +
Bacterial and fungal infections + ++ ++ 0/+ 0/+ +
Specific antibody formation + ++ 0 0 0 0







CMV cytomegalovirus, EBV Epstein-Barr virus, BKV BK virus, IL-2 interleukin 2, Ab antibodies ATG antithymoglobulin, RALI rituximab-associated
lung injury, IVIG intravenous immunoglobulin,
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– Depending on indication, biologics may be used before
and early and late after renal transplantation.
– Clinically additive mechanisms of action promote a com-
bination of these drugs in specific clinical situations, such
as desensitization or humoral rejection.
– Biologic targeting of receptors on different cells may
enhance the risk of serious adverse events, despite spe-
cific prophylactic measures.
Research points in biologics use in rejection therapy are:
– Optimal treatment protocol for chronic humoral rejection
should be established in controlled trials.
– Optimal combinations of biologic agents (and/or extra-
corporeal procedures) aimed to reduce circulating DSA
level for prophylaxis of humoral rejection need to be
established in sensitized candidates for transplantation
and active post-transplant de novo DSA producers
Optimal treatment of primary disease recurrence after
transplantation, including rituximab for NS and
eculizumab for aHUS, should be verified in controlled
trials.
Conflict of interests None.
Questions (answers are provided following the reference list)
1. Monoclonal antibodies (Ab) used in renal transplantation:
a. Are always depleting Ab
b. Are aimed to B cells only
c. May be depleting or blocking Ab
d. Are used only to treat rejection
e. Are not used in children
2. The effect of biologics on specific cell-target receptors:
a. Is always longer with the use of polyclonal Ab
b. Is never longer than 2 weeks after a single dose
c. Is shorter in tacrolimus-treated patients
d. Is drug and dose dependent and may last from 2 weeks to > 12
months
e. Has no clinical importance, as this depends on maintenance
immunosuppression
3. The risk of PTLD is higher in young children receiving biologic agents
after renal transplantation because:
a. They are more frequently desensitized than adolescents
b. They have higher risk of recurrence of primary disease
c. They need more blood transfusions after transplantation
d. They are more often EBV-seronegative < 10 years of age
e. They often have tonsillitis
4. Combination of IVIG and rituximab, used for desensitization or
treatment of humoral rejection:
a. Is given to block T-cell-derived cytokines
b. Allows removal of circulating DSA and blocks their further pro-
duction by B cells
c. Decreases the risk of rituximab-related infectious complications by
IVIG
d. Is not used in children
e. Is used in minimization protocols
5. While administering depletional antibodies:
a. There is no need for monitoring
b.Monitoring drug concentration is mandatory
c. Monitoring target-cell count is useful to assess the effect and
sometimes adjust the next dose
d. Monitoring concomitant CNI concentration is necessary, as there is
CYP3P-driven interaction
e. Every dose must be adjusted to current CD4/CD8 ratio
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